• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23368 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Dipeptidyl-peptidase 4 inhibitors in patients with prediabetes or metabolic syndrome]
2021     Agency for Care Effectiveness (ACE) Photodynamic therapy for treating non-melanoma skin tumours
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selumetinib (treatment of neurofibromas in neurofibromatosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vosoritide (achondroplasia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Tolvaptan in autosomal dominant polycystic kidney disease]
2021     Agency for Care Effectiveness (ACE) Cochlear implants for treating adults with single-sided deafness (SSD)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (acute myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V - Addendum]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Tocilizumab in COVID-19 patients]
2021     Agency for Care Effectiveness (ACE) Antibacterial envelope for the prevention of cardiac implantable electronic device-related infections
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V - Addendum]
2021     Agency for Healthcare Research and Quality (AHRQ) Integrated and comprehensive pain management programs: effectiveness and harms
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Allocation of scarce resources in critical care units in a pandemic]
2021     Agency for Care Effectiveness (ACE) Repetitive transcranial magnetic stimulation for adults with treatment resistant major depressive disorder
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Second addendum to commission A21-84]
2021     Agency for Healthcare Research and Quality (AHRQ) Integrating palliative care in ambulatory care of noncancer serious chronic illness: a mixed-methods review
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Review of the evidence on the impact of school closures through the evolution of the COVID-19 pandemic]
2021     NIHR Health Technology Assessment programme Cognitive–behavioural therapy for a variety of conditions: an overview of systematic reviews and panoramic meta-analysis
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [SGLT2 inhibitors in heart failure]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (malignant pleural mesothelioma) - Addendum to Commission A21-89]
2021     NIHR Health Technology Assessment programme Patch augmentation surgery for rotator cuff repair: the PARCS mixed-methods feasibility study
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Ambulatory oxygen therapy in COVID-19]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Misoprostol (induction of labour) - Benefit assessment according to §35a Social Code Book V]
2021     Agency for Healthcare Research and Quality (AHRQ) Interventional treatments for acute and chronic pain: systematic review
2021     NIHR Health Services and Delivery Research programme Respite care and short breaks for young adults aged 18–40 with complex health-care needs: mixed-methods systematic review and conceptual framework development
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Icosapent ethyl (hypertriglyceridaemia) - Benefit assessment according to §35a Social Code Book V]
2021     Norwegian Institute of Public Health (NIPH) Surgery for carpal tunnel syndrome: a health technology assessment
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Eye controlled speech generating device]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Endo-SPONGE for treating low rectal anastomotic leak. NICE medical technologies guidance 63
2021     NIHR Health Technology Assessment programme Universal late pregnancy ultrasound screening to predict adverse outcomes in nulliparous women: a systematic review and cost-effectiveness analysis
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Risdiplam in spinal muscular atrophy]
2021     Agency for Care Effectiveness (ACE) Golimumab for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tirbanibulin (actinic keratosis) - Benefit assessment according to §35a Social Code Book V]
2021     Agency for Healthcare Research and Quality (AHRQ) Interventions to decrease hospital length of stay
2021     National Institute for Health and Care Excellence (NICE) ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections. NICE medical technologies guidance 62
2021     Norwegian Institute of Public Health (NIPH) Evaluation of tests for FLT3 mutations in acute myeloid leukaemia (AML)
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Stem cell therapy: clinical applications]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2021     National Institute for Health and Care Excellence (NICE) Synergo for non-muscle-invasive bladder cancer. NICE medical technologies guidance 61
2021     NIHR Health Technology Assessment programme DISC: Dupuytren's Interventions Surgery vs. Collagenase. A pragmatic multi-centre randomised controlled non-inferiority, cost effectiveness trial comparing injections of collagenase into the cord to surgical correction in the treatment of moderate Dupuytren's contracture in adult patients
2021     Norwegian Institute of Public Health (NIPH) Subacromial decompression surgery for impingement syndrome: rapid health technology assessment
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Non-invasive respiratory support in Covid-19 patients]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Migalastat (Fabry disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography. NICE medical technologies guidance 60
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Brolucizumab in neovascular age-related macular degeneration]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal or gastro-oesophageal junction cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [COVID-19: follow-up after an acute episode]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Plus Sutures for preventing surgical site infection. NICE medical technologies guidance 59
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Microperimetry in retinopathies]
2021     Agency for Healthcare Research and Quality (AHRQ) Malnutrition in hospitalized adults
2021     NIHR Health Technology Assessment programme Assistive technology and telecare to maintain independent living at home for people with dementia: the ATTILA RCT
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Cardiopulmonary resuscitation in COVID-19 patients]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for updating the DMP "Heart failure"]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical Practice Guideline on adult's palliative care]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Patisiran and inotersen in hereditary transthyretin-mediated amyloidosis]
2021     Agency for Healthcare Research and Quality (AHRQ) Management of high-need, high-cost patients: a "best fit" framework synthesis, realist review, and systematic review
2021     National Institute for Health and Care Excellence (NICE) UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia. NICE medical technologies guidance 58
2021     NIHR Health Technology Assessment programme Impact of multiparametric MRI on staging and management of patients with suspected or confirmed ovarian cancer Short title: MR in Ovarian Cancer (MROC study)
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Whole-exome sequencing in patients with neurological disorders]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Angiotensin II acetate (refractory hypotension in distributive shock) - Addendum to Commission A21-95]
2021     National Institute for Health and Care Excellence (NICE) Danis stent for acute oesophageal variceal bleeding. NICE medical technologies guidance 57
2021     NIHR Health Services and Delivery Research programme Pay More Attention: a national mixed methods study to identify the barriers and facilitators to ensuring equal access to high quality hospital care and services for children and young people with learning disability and their families
2021     NIHR Health Technology Assessment programme UK Cohort study to Investigate the prevention of Parastomal Hernia (CIPHER)
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Transcatheter aortic valve implantation in severe aortic stenosis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vericiguat (cardiac failure) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Alpha-Stim AID for anxiety disorders. NICE medical technologies guidance 56
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating pharmacological treatment for clearing an occluded central venous access device (CVAD)]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Swallowable gastric balloon in obesity]
2021     National Institute for Health and Care Excellence (NICE) Leukomed Sorbact for preventing surgical site infection. NICE medical technologies guidance 55
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Whole exome sequencing in patients with intellectual disability and/or autism spectrum disorder]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Roxadustat (anaemia) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal. NICE medical technologies guidance 54
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Extracranial stereotactic body radiotherapy in oligometastasis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafasitamab (diffuse large cell B-cell lymphoma, combination with lenalidomide) - Assessment according to § 35a (1), Sentence 11, Social Code Book V]
2021     Belgian Health Care Knowledge Centre (KCE) Do innovative medicines against cancer always have a real added value?
2021     National Institute for Health and Care Excellence (NICE) The PLASMA system for transurethral resection and haemostasis of the prostate. NICE medical technologies guidance 53
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Whole exome sequencing in epileptic encephalopathies]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Odevixibat (cholestasis [from 6 months]) - Assessment according to § 35a (1), Sentence 11, Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Baricitinib in COVID-19 patients]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Edaravone in patients with amyotrophic lateral sclerosis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (basal cell carcinoma) - Addendum to Commission A21-97]
2021     Agency for Healthcare Research and Quality (AHRQ) Maternal, fetal, and child outcomes of mental health treatments in women: a systematic review of perinatal pharmacologic interventions
2021     Norwegian Institute of Public Health (NIPH) [Intravenous immunoglobulin treatment in children with PANS/PANDAS conditions]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Hemlibra (emicizumab) – Hemophilia A without inhibitor (re evaluation)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (paroxysmal nocturnal haemoglobinuria) - Benefit assessment according to §35a Social Code Book V]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Lyme disease and persistent symptoms: a look at the current knowledge and recommendations for improving management]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the study protocol and statistical analysis plan on routine practice data collection for onasemnogene abeparvovec - Second addendum to Commission A20-61]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: clinical utility of the different Western blot antigen profiles in the context of disseminated Lyme disease]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis, homozygous F508del mutation in the CFTR gene, 2-5 years) - Benefit assessment according to §35a Social Code Book V (expiry of the limitation period)]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: chronic” Lyme disease: current state of knowledge and overview of the different perspectives]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence on orphan drugs]
2021     NIHR Health Technology Assessment programme Prognostic tools for identification of high risk in people with Crohn’s disease: systematic review and cost-effectiveness study
2021     Scottish Medicines Consortium (SMC) Afamelanotide (Scenesse) for prevention of photoxicity in adult patients with erythropoietic protoporphyria (EPP)
2021     NIHR Health Technology Assessment programme A multicentre randomised controlled trial of induced endometrial trauma in women undergoing first time In Vitro Fertilisation (IVF)
2021     Scottish Medicines Consortium (SMC) Upadacitinib for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)
2021     NIHR Health Technology Assessment programme Risks and benefits of bisphosphonate use in patients with chronic kidney disease: a population-based cohort study
2021     Scottish Medicines Consortium (SMC) Ravulizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): in patients with haemolysis with clinical symptom(s) indicative of high disease activity; in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibalizumab (HIV infection) - Benefit assessment according to §35a Social Code Book V]